The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Risk-adapted autologous transplant in AL amyloidosis: biomarkers and evolving strategies
Heather Landau, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses risk-adapted use of autologous stem cell transplant in amyloid light-chain (AL) amyloidosis. She highlights key cardiac and renal biomarkers used to stratify transplant eligibility, the evolving role of transplant in the era of daratumumab-based therapy, and emerging alternatives for high-risk patients. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
